AEON Biopharma Advances Biosimilar Pathway with FDA Feedback on ABP-450

Event summary

  • FDA provided constructive feedback on AEON Biopharma's analytical similarity strategy for ABP-450 during a BPD Type 2a meeting in January 2026.
  • AEON plans to request a BPD Type 2b meeting in 2026 to discuss next steps for ABP-450 as a biosimilar to BOTOX®.
  • The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually.
  • ABP-450 is already approved as a biosimilar in India, Mexico, and the Philippines.

The big picture

AEON Biopharma's constructive FDA feedback marks a critical step in advancing ABP-450 as a biosimilar to BOTOX®. The company's strategic focus on analytical similarity under the 351(k) pathway aims to reduce clinical study requirements and support full-label market entry. The $3.0 billion U.S. neurotoxin market presents a significant opportunity, but AEON must navigate regulatory and execution challenges to achieve its goals.

What we're watching

Regulatory Pathway
How the FDA's feedback will shape AEON's analytical comparability program and the timeline for a comprehensive similarity package.
Market Dynamics
Whether AEON can capitalize on the $3.0 billion U.S. therapeutic neurotoxin market with ABP-450's full-label approval.
Execution Risk
The pace at which AEON can complete its analytical program and secure a BPD Type 2b meeting in 2026.